Background: Limitations of Existing Double-Strand Break-Based Editing and Epigenetic Data Bottlenecks in Chronic Metabolic Disease R&D

Conventional first-generation CRISPR-Cas9 systems have relied on double-strand break (DSB) approaches to physically cleave DNA and correct genomic information. However, this has exposed critical limitations in clinical and industrial R&D. These include off-target effects, large-scale genomic rearrangements, chromosome loss, and genome instability caused by noise from aberrant cellular structure, all of which have acted as persistent data bottlenecks. Furthermore, the cellular repair mechanisms following double-strand breaks involve random base mutations, making precise control impossible. These limitations lead to unexpected genotoxic responses and feedback loops that compromise efficacy when attempting to maintain effective concentrations in vivo or achieve reversible therapeutic concentrations within the hepatocyte microenvironment. In particular, the inability to dynamically predict and control downstream compensatory feedback circuits that occur in cells after drug exposure has severely limited the design efficiency of computational omics pipelines, creating a data bottleneck that hinders large-scale clinical approval.

Discovery: Activation of Epigenome Writing and Silencing Algorithms and Demonstration of Single-Cell Resolution Independent Variable Tensor Synchronization

To overcome these data barriers, this architecture implements a full-fledged epigenome writing modality that modulates the three-dimensional structural accessibility of chromatin and DNA methylation status without altering the DNA sequence itself. A next-generation computational control system, in which catalytically inactive dCas9 is linked to DNA methyltransferases or demethylases, is synchronized with a metabolic homeostasis regulatory matrix. This system uses differential equation-based in silico calculations to proactively compute the binding free energy of CpG islands located in the promoter regions of target genes, PCSK9 and LDLR, and their downstream transcriptional networks, and removes batch effects. By linking multi-dimensional independent variable tensors extracted from single-cell resolution sequencing data and dynamically programming them on a cellular state transition model, it demonstrates that chromatin openness completely blocks physical access to the transcriptional machinery. A disruptive non-linear graph neural network-based computational algorithm, which surpasses existing simple models, derives PCSK9 protein synthesis inhibition efficiency in real-time and elucidates the topological variation curves of downstream transcriptional networks, thereby demonstrating molecular biological integrity.

Establishment of a Chromatin Promoter Structure Tuning and Reversible Homeostatic Precision Layering Model

The constructed omics matrix backbone contributes to the establishment of a molecular phenotype and family-specific precision layering model by combining patient-specific methylation biomarker profiles and multi-dimensional omics data. This platform transforms omics data from liver tissue of patients with chronic hypercholesterolemia into an AI-based multi-dimensional tensor, precisely distinguishing subtle variations within the patient population. To ensure the reversible persistence of epigenetic silencing, a regulatory loop is introduced that artificially limits the rate-limiting step of methylation in the promoter region. In other words, the activity level of DNA methyltransferase in the target chromatin region is monitored in real-time, and a reversible homeostatic feedback control system is integrated to artificially upregulate or downregulate the activity of specific CpG sites as needed. This creates an autonomous tuning backbone that flexibly maintains therapeutic levels of PCSK9 inhibition while preserving the host cell's inherent transcriptional homeostasis, even in aberrant external stress environments such as severe chronic inflammation or aging.

Prospects: Establishment of a Programmable Epigenetics Standard and Launch of a Next-Generation IND Digital Governance System

This programmable epigenome editing architecture establishes a standard that completely transforms the paradigm of global new drug R&D governance from a static, post-hoc symptomatic approach to a multi-dimensional computational tensor-based predictive infrastructure. This will accelerate the pipeline expansion of multinational pharmaceutical companies. By linking expression gradient correction coefficients based on genetic background diversity in high-throughput screening, it solidifies a computational moat that computationally eliminates epigenetic deviations that occur between cell culture batches. Furthermore, it fully meets the digital healthcare-based companion diagnostic (CDx) specifications required by global regulatory agencies such as the U.S. FDA, and functions as a master digital asset that disruptively shortens the simulation timeline for clinical trial protocol review and approval. Ultimately, it will establish a global commercialization standard for next-generation epigenome editing therapeutics by providing consistent batch production assurance and total data reliability up to the cGMP commercial launch stage.